Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 3, 1996, Pages 322-331

  Eap, Chin B ^a   Guentert, Theo W ^b   Schäublin Loidl, Martina ^b   Stahl, Max ^b   Koeb, Liliane ^b   Powell, Kerry ^b   Baumann, Pierre ^b  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; DRUG METABOLITE; MEPHENYTOIN; MESORIDAZINE; MOCLOBEMIDE; PLACEBO; THIORIDAZINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; STEREOSPECIFICITY;

ADULT; AGED; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEPHENYTOIN; MESORIDAZINE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTHIAZINES; STEREOISOMERISM; THIORIDAZINE;

EID: 0029897864     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)80010-5     Document Type: Article

References (34)

1. Niedzwiecki DM, Mailman RB, Cubeddu LX. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. J Pharmacol Exp Ther 1984;228:636-9.
2. Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striaturn. J Pharmacol Exp Ther 1989;250:117-25.
3. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982;4:33-40.
4. Heath A, Svensson C, Martensson E. Thioridazine toxicity - an experimental cardiovascular study of thioridazine and its major metabolites in overdose. Vet Hum Toxicol 1985;27:100-5.
5. Juenge EC, Wells CE, Green DE, Forrest IS, Shoolery JN. Synthesis, isolation, and characterization of two stereoisomeric ring sulfoxides of thioridazine. J Pharm Sci 1983;72:617-21.
6. Eap CB, Koeb L, Powell K, Baumann P. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. J Chromatogr B 1995;669:271-9.
7. Svendsen CN, Froimowitz M, Hrbek C, et al. Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain. Neuropharmacology 1988;27: 1117-24.
8. Jortani SA, Poklis A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J Anal Toxicol 1993;17:374-7.
9. Eap CB, Souche A, Koeb L, Baumann P. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine. Ther Drug Monit 1991;13:356-62.
10. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
11. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990;46:377-94.
12. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. CLIN PHARMACOL THER 1991;49:234-40.
13. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
14. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
15. Breimer DD, Dengler HJ, Eichelbaum M, et al. Report on the workshop "Molecular basis of polymorphic drug oxidation in man," Otzenhausen, 1983. Eur J Clin Pharmacol 1984;27:253-7.
16. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
17. Baumann P, Jonzier-Perey M. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 1988; 171:211-22.
18. Sanz EJ, Villen T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. CLIN PHARMACOL THER 1989;45: 495-9.
19. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-2.
20. Eap CB, Koeb L, Baumann P. Artifacts in the analysis of thioridazine and other neuroleptics. J Pharm Biomed Anal 1993;11:451-7.
21. Syvälahti EKG, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986;22:89-92.
22. Spina E, Martines C, Caputi AP, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991;41:467-70.
23. Meyer JW, Woggon B, Baumann P, Meyer UA. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990;39:613-4.
24. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
25. Brøsen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 1989;37:155-60.
26. Baumann P, Meyer JW, Amey M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992;14:1-8.
27. Gram LF, Brøsen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993;35:649-53.
28. Baumann P, Eap CB, Koeb L, et al. Pharmacogenetic investigations in moclobemide (MOCL) + thioridazine (THD) vs MOCL + placebo treated depressive patients [Abstract]. Neuropsychopharmacology 1994;10:75S.
29. von Bahr C, Spina E, Birgersson C, et al. Inhibition of desmethylimipramine 2-hydraxylation by drugs in human liver microsomes. Biochem Pharmacol 1985;34: 2501-5.
30. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
31. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. CLIN PHARMACOL THER 1992;52:350-8.
32. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. CLIN PHARMACOL THER 1991;49:18-23.
33. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15: 11-7.
34. Lin G, Hawes EM, McKay G, Korchinski ED, Midha KK. Metabolism of piperidine-type phenothiazine antipsychotic agents; IV: thioridazine in dog, man and rat. Xenobiotica 1993;23:1059-74.